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Labeled antibodies, as well as their fragments and antibody-derived recombinant
constructs, have long been proposed as general vectors to target radionuclides to tumor
lesions for imaging and therapy. They have indeed shown promise in both imaging and
therapeutic applications, but they have not fulfilled the original expectations of achieving
sufficient image contrast for tumor detection or sufficient radiation dose delivered to
tumors for therapy. Pretargeting was originally developed for tumor immunoscintigraphy.
It was assumed that directly-radiolabled antibodies could be replaced by an unlabeled
immunoconjugate capable of binding both a tumor-specific antigen and a small molecular
weight molecule. The small molecular weight molecule would carry the radioactive
payload and would be injected after the bispecific immunoconjugate. It has been
demonstrated that this approach does allow for both antibody-specific recognition and
fast clearance of the radioactive molecule, thus resulting in improved tumor-to-normal
tissue contrast ratios. It was subsequently shown that pretargeting also held promise
for tumor therapy, translating improved tumor-to-normal tissue contrast ratios into more
specific delivery of absorbed radiation doses. Many technical approaches have been
proposed to implement pretargeting, and two have been extensively documented.
One is based on the avidin-biotin system, and the other on bispecific antibodies
binding a tumor-specific antigen and a hapten. Both have been studied in preclinical
models, as well as in several clinical studies, and have shown improved targeting
efficiency. This article reviews the historical and recent preclinical and clinical advances
in the use of bispecific-antibody-based pretargeting for radioimmunodetection and
radioimmunotherapy of cancer. The results of recent evaluation of pretargeting in PET
imaging also are discussed.
Keywords: pretargeting, immunoscintigraphy, immuno-PET, radioimmunotherapy, bispecific antibody
Abbreviations: CEA, carcinoembryonic antigen; CRC, colorectal carcinomas; Ct, calcitonin; DNL, Dock-and-Lock; DT,
doubling times; DTPA, diethylene triamine pentaacetic acid; FDG, 18 F-fluoro-deoxy-glucose; F-DOPA, L-3,4-Dihydroxy-
6-[18 F]fluorophenylalanine; HSG, histidine-succinyl-glycine; MTC, medullary thyroid carcinoma; OS, overall survival; PET,
positron emission tomography; RIT, radioimmunotherapy; SPECT, single photon emission tomography.
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Introduction
The idea of using antibodies to specifically deliver toxic agents to
tumor cells emerged a long time ago, and was subsequently pro-
posed to target radionuclides for tumor detection and imaging
(Goldenberg et al., 1974). The concept was revived after the intro-
duction of monoclonal antibodies, which made the development
of immunoconjugates and radiolabeled compounds much easier
(Kohler and Milstein, 1975). The most straightforward applica-
tion was tumor imaging, since it directly showed if the result is
reached: namely, was the activity concentrated on the target or
not? In the mid-eighties, imaging was performed by scintigra-
phy with gamma emitters, such as iodine-131, indium-111, or
technetium-99m. Initial results were remarkable, especially in
preclinical models. Translation into humans followed, but sen-
sitivity and specificity were not sufficient for a real commercial
success, although some radiolabeled antibodies (e.g., oncoscint,
CEA-Scan, prostascint, leukoscan) received market approval
(Goldenberg, 1997). Thus, developing new approaches to achieve
a higher tumor signal over adjacent normal tissues became a
very active field of research. Goodwin and co-workers proposed
the use of a specific immunoconjugate recognizing both a tar-
get antigen and a low-molecular-weight substance to which a
radionuclide was bound (Goodwin et al., 1988). The unlabeled
tumor-specific agent and the substance carrying the radionuclide
would be injected sequentially. The rationale was that the bispe-
cific immunoconjugate would decorate tumor cells with binding
sites for the small labeled molecule, which would then bind the
targets quickly with fast excretion of excess unbound activity.
This approach was called pretargeting.
Pretargeting can be achieved using many different techniques
(Goldenberg et al., 2006). Antibodies or antibody fragments
usually provide specific binding to target tumors, but differ-
ent substances have been proposed for the second recognition
step. A second antibody may be used to bind a small molecule,
called a hapten by immunologists, or avidin/streptavidin to bind
biotin (Paganelli et al., 1991), or a nucleotide to bind a second
nucleotide of complementary sequence (Bos et al., 1994). Many
other receptor-ligand or enzyme-substrate systems could be used
as well, and the pros and cons of these methods have been pre-
viously discussed (Goldenberg et al., 2003; Paganelli and Chinol,
2003). It is not the scope of the present review to describe all these
approaches. Our focus is on reviewing antibody-based recog-
nition systems: “bispecific” antibodies and radiolabeled haptens
(Chang et al., 2002).
It became rapidly apparent that tumors not expressing the
target antigen, whilst being a true-negative in molecular terms,
would score as false-negatives following immunoscintigraphy.
At about the same time, positron emission tomography (PET)
imaging and 18F-fluoro-deoxy-glucose (FDG) appeared as a
general, sensitive, and rather specific tumor detection method
(Delbeke, 1999). Immunoscintigraphy, including pretargeted
immunoscintigraphy, was soon considered obsolete. Following
this it was found that pretargeting, using either the avidin/biotin
or bispecific antibody techniques, was capable of delivering a
high fraction of injected activity to tumors, and that tumor
accretion was protracted enough to deliver high tumor absorbed
doses if a therapeutic radionuclide was used for cancer therapy
instead of imaging (Goldenberg et al., 2006). Thus, pretarget-
ing became recognized as a promising approach for targeted
radionuclide therapy. Even more recently, antibodies have been
labeled with positron-emitters (van Dongen and Vosjan, 2010).
Current improvements in antibody specificity and radiolabeling
methods coupled with more sensitive and higher resolution PET
imaging, makes immuno-PET a feasible approach both as a diag-
nostic tool or companion diagnostic, especially in the context of
antibody-based cancer therapy. Pretargeting improves the per-
formance of immuno-PET and allows for the use of short half-
life positron-emitting radionuclides that would reduce patient
irradiation.
The results obtained from preclinical experiments and clini-
cal applications for both imaging and therapy will be discussed,
along with recent results in pretargeted PET imaging.
Pretargeting with Bispecific Antibodies
and Radiolabeled Haptens
Radiolabeled antibodies in the form of whole IgGmolecules show
slow pharmacokinetics. Whilst tumor accretion may reach fairly
high levels (more than 10% of injected activity per gram of tumor
in mice, and sometimes as high as 0.1% per gram of tumor in
humans), this is obtained only hours or days after activity injec-
tion, and circulating unbound activities remain elevated for days
(Chang et al., 2002). Using alternative antibody formats, such
as antibody fragments or low-molecular weight recombinant
molecules, can enhance certain targeting properties, but there is
an inevitable trade-off between tumor accretion and clearance of
excess unbound activity (Jain et al., 2007). Fine-tuning a targeting
strategy that preserves the high tumor accretion observed with
directly radiolabeled IgG, whilst rapidly eliminating non-targeted
radioactivity from the blood and normal tissues to increase
tumor-to-normal tissue ratios and minimize toxicity has been an
active research field since the mid-eighties.
As mentioned, Goodwin et al. (1988; Goldenberg, 1997) pro-
posed the use of a specific immunoconjugate that recognizes
both the target antigen and a low-molecular-weight substance to
which the radionuclide is bound. The unlabeled tumor-seeking
agent and the substance carrying the radionuclide are injected
sequentially. The radioactive compound is administered only
after the antibody has localized in the target lesion and its excess
has cleared, at least in part, from the circulation. This was first
achieved using a bispecific antibody binding both a target anti-
gen and a radiometal-chelate complex (Stickney et al., 1991;
Lollo et al., 1994). In the early days of pretargeting, the main
objective was tumor imaging, and indium-111 was considered
the radionuclide of choice. More specifically, an indium-benzyl-
EDTA complex was used as a hapten and bispecific antibodies
binding carcinoembryonic antigen (CEA) and the hapten were
used in the preclinical and clinical settings (Stickney et al., 1991;
Lollo et al., 1994). Whilst the results were encouraging, if the
injected dose of bispecific antibody was low or the delay between
bispecific antibody and hapten injections was too long, low tumor
uptake was observed. Conversely, with a high dose of bispecific
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antibody and a short delay, tumor uptake was appreciable, but
retention of the radioactive hapten in the circulation was high
and protracted. A significant improvement was thus necessary.
The Affinity Enhancement System
The use of bivalent haptens was proposed by Le Doussal et al.
(1989, 1990). The idea was that bivalence could cross-link bispe-
cific antibody molecules at the surface of target cells, resulting in
a cooperative binding and enhanced affinity (or avidity), whereas,
in the circulation, binding would remain rapidly reversible. This
is why this technique was called the “Affinity Enhancement Sys-
tem” or AES (Figure 1). It must be noted that because of the avid-
ity effect, no chase of excess bispecific antibody is necessary with
AES, and surprisingly, the distance between the two haptens does
not need to be very long. For instance, the tyrosyl-lysine dipep-
tide, substituted by DTPA on both the α-NH2 of the tyrosine and
the ε-NH2 of the lysine, allows for the simultaneous binding of
two anti-DTPA-indium antibodies, as shown by in vitro sandwich
assays (Le Doussal et al., 1990).
This concept was used by Goodwin et al., who confirmed the
superiority of bivalent haptens in this context (Goodwin et al.,
1992, 1994), and proposed its use for therapy using a monoclonal
antibody raised against the yttrium-DOTA hapten. Later on, sim-
ilar results were published that further confirmed the advantage
of using bivalent haptens (Kranenborg et al., 1998; Boerman
et al., 1999) using a hybrid hybridoma obtained by somatic fusion
of the anti-renal cell carcinoma antibody G250 with an anti-
DTPA-indium antibody. Soon, indium-111 scintigraphy imaging
studies were translated to the clinic, which afforded high con-
trast images (Le Doussal et al., 1993; Peltier et al., 1993; Vuillez
et al., 1997; Barbet et al., 1998), particularly in medullary thy-
roid carcinoma (MTC), a tumor that consistently expresses high
levels of CEA. The bispecific antibody F6x734 recognized CEA
on one side and the hapten indium-DTPA on the other. It was
merely a chemical conjugate of two Fab fragments. The bivalent
hapten was prepared by derivatizing tyrosyl-lysine with DTPA
anhydride. This bivalent hapten could be labeled with indium-
111, but also radio-iodinated. However, the antibody was specific
for the indium-DTPA complex and other metal radionuclides
could not be used. Bispecific antibodies and bivalent haptens
based on the histidine-succinyl-glycine (HSG) pseudo-peptide
were then proposed (Janevik-Ivanovska et al., 1997). New biva-
lent haptens based on this HSG structure that may be labeled
using a variety of radionuclides are currently used for pretargeted
radioimmunotherapy and immuno-PET.
Pretargeted Radioimmunotherapy (pRIT)
By the time these preliminary clinical studies of tumor imaging
were completed, FDG-PET was developed for staging and ther-
apy evaluation in solid tumors and lymphomas (Bos et al., 1994).
Specific delivery of indium-111 to tumors using pretargeting was
highly specific, but missed antigen-negative tumor sites or those
expressing very low levels of target antigen, resulting in moderate
sensitivity (Barbet et al., 1998). In contrast, FDG-PET proved to
have excellent sensitivity and good specificity for many different
FIGURE 1 | The concept of pretargeting with the Affinity Enhancement
System. First Step: A bispecific antibody, designed to bind by one arm a
tumor antigen (e.g., carcinomembryonic antigen) and by the other a hapten
(e.g., the indium-DTPA complex or the HSG pseudo-peptide), is injected first.
It distributes in the body and binds the tumor. Second Step: After an interval of
several hours to a few days, the bispecific antibody has cleared from the
circulation and the radiolabeled bivalent hapten is injected. It binds rapidly to
the tumor. At the tumor cell surface, hapten bivalency induces cooperativity
that results in very slow release.
solid tumors and aggressive lymphomas. The ability of a single
agent to image most tumors and the high sensitivity and resolu-
tion of PET cameras made the technique extremely successful.
Most efforts in the development of radiolabeled antibodies for
scintigraphy were soon discontinued. However, preclinical stud-
ies had shown that pretargeting could compare favorably with
directly labeled antibodies for therapy. Pretargeting was shown
to be able to deliver tumoricidal radiation doses (Gautherot
et al., 1998) and cure mice bearing human tumor xenografts
(Kraeber-Bodéré et al., 1999a; Gautherot et al., 2000).
Monoclonal antibodies have been regarded for years as
ideal to deliver radionuclides to disseminated tumor cells,
and the most convincing results in radioimmunotherapy (RIT)
have been obtained with antibodies to B-lymphocyte differen-
tiation antigens (CD20, CD22, CD37, HLA-DR) to treat B-
cell lymphomas. Most of these antibodies produce significant
intrinsic anti-tumor activity (e.g., rituximab) by triggering
immune defense mechanisms (Maloney et al., 1997). The acces-
sibility of target cells to blood-borne therapy and the high
radiosensitivity of lymphomas account for the observed clinical
Frontiers in Pharmacology | www.frontiersin.org 3 March 2015 | Volume 6 | Article 54
Kraeber-Bodéré et al. Pretargeted immune-PET and RIT
efficacy, which can be considered as a real breakthrough in
the treatment of chemoresistant forms of these cancers (Wilder
et al., 1996). Two anti-CD20 radiolabeled antibodies have been
marketed: 131I-tositumomab (Bexxar R©, GlaxoSmithKline) and
90Y-ibritumomab tiuxetan (Zevalin R©, Spectrum Pharmaceuti-
cals, Henderson, NV, USA), whilst Bexxar has been recently
discontinued.
Monoclonal antibodies have also shown efficacy in the treat-
ment of solid tumors, generally in combination with chemother-
apy. Trastuzumab and other antibodies targeting growth factor
receptors are now on the market. Many other antibodies with
very high specificity for solid tumors are available [e.g., anti-CEA
antibodies for colorectal carcinomas (CRC), MTC, breast can-
cers, or lung cancers]. However, poor tumor accessibility and
low radiosensitivity characterize most solid tumors. As a result,
clinical trials with radiolabeled antibodies to date have provided
limited and contested results for solid tumor RIT. Antibodies
or antibody fragments labeled with β−-emitting radioisotopes
(iodine-131, yttrium-90, rhenium-186 or 188, copper-67) still
deliver toomuch radiation to normal organs compared to tumor-
specific exposure (Wilder et al., 1996).
In these cases, pretargeted RIT could increase the therapeu-
tic index as it increases tumor-to-normal tissue uptake ratios,
and increases radiation doses delivered to tumor cells in the
clinic, as it does in preclinical models. A phase I/II clinical
trial was implemented in 1996 to evaluate toxicity, pharma-
cokinetics, dosimetry, and antitumor activity, using the murine
anti-CEA bispecific antibody F6x734 and the bivalent indium-
DTPA hapten labeled with iodine-131 in 26 patients with recur-
rence of MTC (Kraeber-Bodéré et al., 1999b). Hematotoxicity
was the dose-limiting toxicity. The maximum tolerated activ-
ity was relatively low (1.8GBq/m2), because diffuse bone mar-
row involvement appeared to be more frequent than previously
reported in patients with metastatic MTC (Mirallié et al., 2005).
Some therapeutic response was observed, and was mainly in
patients with a small tumor burden and after repeated courses
FIGURE 2 | Pretargeted immuno-PET recorded after injection of 120nmol of TF2 and 6nmol of 68Ga-IMP-288 at 30h in a patient with a relapse of
MTC. Immuno-PET shows bone marrow lesions.
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of pretargeted RIT. Because of frequent immune responses, a
chimeric (hMN14x734) bispecific antibody was developed. A
prospective phase I optimization study was performed in 34
patients with CEA-expressing tumors, including MTC and other
carcinomas, to determine the optimal bispecific antibody dose,
hapten activity, and pretargeting interval (Kraeber-Bodéré et al.,
2003, 2006).
A major and rather unexpected outcome of these studies was
the high number of patients with long-term disease stabiliza-
tion, which was observed in 53% of the MTC patients based
on morphological imaging assessment (computed tomography,
MRI) and biomarker evaluation using serial calcitonin (Ct) and
CEA measurements. A retrospective study compared the overall
survival (OS) of 29 MTC patients treated by pretargeted RIT in
the 2 phase I/II trials previously presented, against 39 contem-
poraneous untreated patients for whom data were collected by
the French Endocrine Tumor Group (GTE) (Chatal et al., 2006).
Since Ct and CEA doubling times (DT) had been shown to be
of a prognostic value for survival in MTC (Barbet et al., 2005),
patients were stratified accordingly; OS was significantly longer
in high-risk (Ct DT < 2 years) treated compared to high-risk
untreated patients (median OS, 110 vs. 61 months; P < 0.030).
Ct DT variations were proposed as a surrogate marker for sur-
vival by comparing, among treated patients, the survival of bio-
logical responders and non-responders. Defining a responder as
showing at least a 100% increase (doubling) in Ct DT, 47% of bio-
logical responders experienced significantly longer survival than
non-responders (median OS, 159 vs. 109 months; P < 0.035) or
untreated patients (median OS, 159 vs. 61 months; P < 0.010).
Treated patients with bone/bone marrow disease had a longer
survival than patients without such involvement (10-year OS of
83 vs. 14%; P < 0.023). Toxicity was mainly hematological and
related to bone marrow involvement, and was treated by platelet
infusions or G-CSF injections. Interestingly, no other toxicity,
especially renal toxicity, was reported.
A prospective phase II pretargeted RIT trial was undertaken
in progressive MTC patients, progression being defined biolog-
ically by a Ct DT shorter than 5 years (Salaun et al., 2012).
Forty-five patients were enrolled. Three patients did not complete
the treatment, two due to reactions during bispecific antibody
infusion, and hapten-labeling failure in one. Patients received
40mg/m2 of hMN-14x734, followed by 1.8 GBq/m2 of biva-
lent indium-DTPA hapten labeled with iodine-131 given 4–6
days later. According to RECIST morphological imaging crite-
ria, the disease control rate (durable stabilization plus objec-
tive response) was 76.2%, including a durable complete response
of at least 40 months in one patient (2.4%), and durable sta-
ble disease (≥6 months) in 31 patients (73.8%). Tumor uptake
assessed by post-pretargeted RIT immunoscintigraphy predicted
significantly the tumor response. After RIT, 21 of 37 assessed
patients (56.7%) showed a ≥100% increase in Ct or CEA DT
or prolonged decrease of the biomarker concentration. Interest-
ingly, biomarker DT and FDG-PET response after pretargeted
RIT showed a prognostic value for OS, suggesting these data
might serve as surrogate markers for prognostically favorable
patients (Salaun et al., 2014). As expected, in the patients with
a high frequency of diffuse bone marrow involvement, grade 3
and 4 hematologic toxicity was observed (54.7% of patients), and
myelodysplastic syndrome was reported in two cases, including
one previously heavily treated patient.
Current Research on Pretargeting
The use of indium-DTPA as a hapten for pretargeting is known to
be problematic, because labeling is only possible with indium-111
or iodine-123 for scintigraphy, iodine-124 for PET or iodine-
131 for therapy. Interest therefore switched to another hap-
ten, histamine-succinyl-glycine (HSG). Several different bivalent
structures were developed with a view to make labeling possible
with a variety of radionuclides. A bivalent HSG hapten that could
FIGURE 3 | Pretargeted immuno-PET recorded after injection of 120nmol of TF2 and 6nmol of 68Ga-IMP-288 at 42h in a patient with a relapse of
MTC. Immuno-PET (A) shows right neck lymph nodes not detected by F-DOPA-PET (B).
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be labeled with technetium-99m or rhenium-186/188 was pro-
duced first (Gestin et al., 2001). Subsequently, a series of bivalent
HSG haptens was synthesized by Goldenberg and coworkers that
could be labeled with a variety of radionuclides (Sharkey et al.,
2003; McBride et al., 2006). One of them, IMP 288, was used
in many preclinical and clinical studies. Labeling with iodine-
124 and gallium-68 was used for immuno-PET and a method to
label this peptide with fluorine-18 was also described (McBride
et al., 2009; Schoffelen et al., 2010a). For therapy, IMP 288 was
labeled with yttrium-90 (Karacay et al., 2009) and lutetium-177
(Schoffelen et al., 2010b).
To further advance the clinical applications of pretarget-
ing, it also became clear that humanized recombinant bispecific
antibodies must be produced. Although many different for-
mats of bispecific antibodies had been proposed, mass produc-
tion under GMP conditions proved quite difficult. Eventually,
Immunomedics, Inc., developed a new approach they refer to
as the Dock-and-Lock™ (DNL) method (Rossi et al., 2006). The
DNL method uses the regulatory subunits of cAMP-dependent
protein kinase and the anchoring domains of A kinase to con-
struct conjugates of antibody Fab fragments that are bispecific
and trivalent, with a single binding site for the hapten and
two binding sites for the tumor antigen. They have successfully
produced several DNL™ conjugates binding CEA (TF2), CD20
(TF4), a mucin antigen expressed by pancreatic tumors (TF10),
and the Trop-2 antigen (TF12) (Govindan and Goldenberg, 2010;
Sharkey et al., 2012). Through these remarkable achievements,
using this technology, radionuclide pretargeting is now possible
against a wide spectrum of target antigens, and allows a vari-
ety of radionuclides for PET imaging and therapy to be mobi-
lized (Karacay et al., 2009; Schoffelen et al., 2010b, 2012; van Rij
et al., 2013). The first clinical results of an optimization study
assessing the anti-CEA× anti-HSG bsMAb TF2 and the radiola-
beled hapten-peptide, 177Lu-IMP288, in patients with metastatic
CRC have been reported recently (Schoffelen et al., 2013). Dif-
ferent schedules were studied in four cohorts of five patients: (1)
shortening the interval between the bsMAb and peptide admin-
istration (5 days to 1 day), (2) escalating the TF2 dose (from
75 to 150 mg), and (3) reducing the peptide dose (from 100 to
25µ g). Rapid and selective tumor uptake was detected within
1 h after the peptide injection, with high tumor-to-tissue ratios at
24 h. The best tumor targeting was achieved with a 1-day pretar-
geting interval and with the 25-µg peptide dose. High activities
of 177Lu-IMP288 (2.5–7.4 GBq) were well-tolerated, with some
manageable reactions during the TF2 infusions, and transient
grade 3–4 thrombocytopenia in 10% of the patients. Dosimetry
estimations concluded that renal and red bone marrow uptake of
177Lu-IMP288 peptide was relatively low, even if marrow doses
increased in subsequent cohorts as the TF2/Lu-IMP288 ratio
was increased (Schoffelen et al., 2014). The predicted kidney
absorbed doses (<0.50 mGy/MBq) did not limit the maximum
activity that could be administered. None of the patients exceeded
the limit of 15 Gy to the kidneys with four cycles of 7.4 GBq
177Lu-IMP288. Two phase-I clinical trials are on-going in France,
assessing pretargeted 177Lu-IMP288 (one injection) in patients
with metastatic CEA-positive lung carcinoma, and fractionated
injection of 90Y-IMP288 in metastatic CRC patients.
Preclinical pharmacokinetic and dosimetry studies have
shown that high radiation doses could be delivered to tumor
cells, with limited irradiation of normal tissues (Frampas et al.,
2011). These studies have also demonstrated that pretargeting
using DNL bispecific antibodies would be most useful for deliver-
ing short half-life radionuclides. Indeed, the fast tumor uptake of
activity afforded by this pretargeting technique would be suitable
for radionuclides with half-lives of a few hours. Since all pretar-
geting optimization studies using the DNL bispecific antibodies
have shown that a large molar excess of bispecific antibody rela-
tive to the molar amount of hapten should be used, a potentially
limiting factor is the specific activity at which the bivalent haptens
(e.g., IMP 288) may be labeled, which is also, at least theoretically,
in favor of short half-life radionuclides. In preclinical studies with
lutetium-177, the limited specific activity was overcome by using
repeated injections of both the bispecific antibody and IMP 288
labeled with lutetium-177 (van Rij et al., 2013). Also, yttrium-90
outperformed lutetium-177 in this context, and short half-life
alpha-particle-emitting radionuclides, such as astatine-211 or
bismuth-213, should be considered (Frampas et al., 2011).
FIGURE 4 | Pretargeted immuno-PET recorded after injection of
120nmol of TF2 and 3nmol of 68Ga-IMP-288 at 30h in a patient with
metastatic breast carcinoma. Immuno-PET (A,C) shows a high tumor
uptake and a higher number of lesions as compared to FDG-PET (B,D).
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Pretargeted Immuno-PET
The ability of pretargeting to deliver activity within a few hours
and to achieve high tumor-to-background activity ratios revived
the idea of antibody-targeted in vivo imaging. Obviously a
most attractive approach in this context would be PET, and
the major justification for antibody-targeted in vivo imaging
would be to select patients who could benefit from antibody-
targeted therapy, because their tumors express the target anti-
gen. This would replace tumor biopsy, which obviously cannot
be performed for all known tumor lesions and is not fully accu-
rate because a biopsy may not be representative of the whole
tumor.
PET, with its improved sensitivity and better resolution, as
compared to scintigraphy and SPECT in humans, is indeed
expected to provide useful clinical information. PET imaging
with IgG antibodies labeled with long-lived positron-emitting
radionuclides, such as zirconium-89, has been shown to be quite
effective for in vivo tumor detection and to demonstrate antigen
expression (Vugts et al., 2013). However, PET must be recorded
days after activity injection for optimal contrast, and these long-
lived radionuclides that emit, in addition to a positron, gamma
rays of high energy have an unfavorable dosimetry. Pretarget-
ing makes possible the use of short-lived radionuclides, such
as gallium-68, but also fluorine-18. The PET images may be
recorded only a few hours after activity injection. This has already
been shown in preclinical studies (McBride et al., 2006; Schoffe-
len et al., 2010a, 2012), and clinical trials are in progress that show
very promising sensitivity and specificity (Schuhmacher et al.,
2001). Two clinical trials are on-going in France, aiming at opti-
mizing and assessing pretargeted immuno-PET, using anti-CEA
TF2 and 68Ga-IMP288 in patients with relapsedMTC andHER2-
negative breast cancer. In each study, four or five cohorts of three
patients are compared to determine the best TF2/IMP-288 molar
dose ratio and the best pretargeted delay. Figure 2 illustrates the
high tumor uptake obtained with this approach in a MTC patient
with bone marrow lesions, injected with 120 nmol of TF2 and
6 nmol of 68Ga-IMP-288 30 h later. In some cases, immuno-PET
allowed detection of lesions not detected by F-DOPA-PET, con-
sidered as reference PET imaging in MTC (Figure 3). Promis-
ing results were also obtained in a CEA-positive breast cancer
patients (Figure 4).
Conclusions and Perspectives
Pretargeting is an old idea originating in the mid-80s. Sev-
eral approaches have been developed and tested in preclin-
ical models and clinical trials. Here, approaches that use
bispecific antibodies targeting a tumor antigen and a hap-
ten have been discussed and the superiority of bivalent hap-
tens has been stressed. Originally, pretargeting was developed
for in vivo imaging using single-photon scintigraphy until
FDG-PET become so popular because it demonstrated such
high sensitivity in a large number of tumors, while antibody-
targeted radionuclides could only target tumors expressing spe-
cific antigens. Following this, pretargeting was also considered
for radionuclide therapy. Phase I and II clinical studies demon-
strated the efficacy of anti-CEA pretargeting in rapidly pro-
gressive metastatic MTC patients, paving the way for future
studies.
Today, a new generation of pretargeting compounds are avail-
able. A series of humanized recombinant trivalent bispecific
antibodies based on DNL technology have been produced by
Goldenberg and coworkers. They recognize antigens of high
interest, including CEA, CD20, Trop-2, and the hapten peptide,
HSG, which may easily be labeled with a large variety of radionu-
clides (Sharkey et al., 2003; McBride et al., 2006). They may be
produced in large amounts and may be used in the clinic for both
imaging and therapy.
Several preclinical studies of pretargeted radionuclide therapy
using these new compounds have produced promising results
and clinical trials are in progress. The very fast delivery of
radionuclides using this pretargeting approach makes it possible
to develop immuno-PET with short half-life positron-emitters.
This has been established in preclinical studies and clinical tri-
als are in progress, confirming that high quality images can be
obtained.
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